CBUS · Insider Trading
Cibus, Inc. Class A Common Stock
Every open-market purchase and sale reported by CBUS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-10 | Craig Wichner | CEO | A | +894,309 | — |
| 2026-06-04 | Gerhard Prante | Director | A | +64,748 | — |
| 2026-06-04 | Kimberly Ann Box | Director | A | +77,586 deriv. | — |
| 2026-06-04 | Craig Wichner | Director | A | +77,586 deriv. | — |
| 2026-06-04 | Rory B Riggs | Director | A | +77,586 deriv. | — |
| 2026-06-04 | Jean-Pierre Jules Lehmann | Director | A | +64,748 | — |
| 2026-06-04 | Thomas Urban | Director | A | +64,748 | — |
| 2026-06-04 | Mark Terrence Finn | Director | A | +77,586 deriv. | — |
| 2026-06-04 | August J Moretti | Director | A | +77,586 deriv. | — |
| 2026-04-28 | Gregory Francis William Gocal | Chief Scientific Officer & EVP | A | +57,000 | — |
| 2026-04-28 | Thomas Urban | Director | A | +9,094 deriv. | — |
| 2026-04-28 | Jason Stokes | CAO, Gen Csl & Corp Secy | A | +57,000 | — |
| 2026-04-28 | Noel Sauer | Sr VP, Research | A | +38,000 | — |
| 2026-04-28 | Carlo Broos | CFO | A | +57,000 | — |
| 2026-04-28 | Carlo Broos | CFO | A | +57,000 | — |
| 2026-04-28 | Peter Beetham | Interim CEO, Pres & COO | A | +195,000 | — |
| 2026-04-01 | Noel Sauer | Sr VP, Research | F | −1,763 | −$3.24K |
| 2026-04-01 | Peter Beetham | Interim CEO, Pres & COO | F | −16,112 | −$29.81K |
| 2026-04-01 | Gregory Francis William Gocal | Chief Scientific Officer & EVP | F | −8,954 | −$16.30K |
| 2026-04-01 | Jason Stokes | CLO, Gen Csl & Secy | F | −3,695 | −$6.76K |
| 2026-04-01 | Carlo Broos | CFO | F | −3,676 | −$6.87K |
| 2026-03-18 | Noel Sauer | Sr VP, Research | MIXED | −1,838 | −$2.43K |
| 2026-03-18 | Jason Stokes | CLO, Gen Csl & Secy | F | −13,109 | −$30.08K |
| 2026-03-18 | Carlo Broos | CFO | F | −1,496 | −$1.97K |
| 2026-02-02 | Rory B Riggs | Director | A | +333,333 | +$500.00K |
| 2026-02-02 | Jean-Pierre Jules Lehmann | Director | A | +666,666 | +$1000.00K |
| 2025-11-25 | Craig Wichner | Director | A | — | — |
| 2025-09-26 | Kimberly Ann Box | Director | A | +54,722 deriv. | — |
| 2025-06-11 | Rory B Riggs | Director | X | +4,050,000 | +$900 |
| 2025-06-10 | Rory B Riggs | Director | A | +5,714,286 | +$10.00M |
| 2025-05-27 | Mark Terrence Finn | Director | A | +39,301 deriv. | — |
| 2025-05-27 | Rory B Riggs | Director | A | +39,301 deriv. | — |
| 2025-05-27 | Gerhard Prante | Director | A | +32,490 | — |
| 2025-05-27 | August J Moretti | Director | A | +39,301 deriv. | — |
| 2025-05-27 | Jean-Pierre Jules Lehmann | Director | A | +32,490 | — |
| 2025-05-27 | Keith Allen Walker | Director | A | +39,301 deriv. | — |
| 2025-03-28 | Noel Sauer | SVP, Research | A | +11,750 | — |
| 2025-03-28 | Jason Stokes | CLO, Gen Csl & Secy | A | +28,250 | — |
| 2025-03-27 | Gregory Francis William Gocal | Chief Scientific Officer & EVP | A | +60,000 | — |
| 2025-03-27 | Peter Beetham | President and COO | A | +125,500 | — |
| 2025-03-27 | Carlo Broos | Interim CFO | A | +28,250 | — |
| 2025-02-26 | Gerhard Prante | Director | Sell | −1,150 | −$2.21K |
| 2025-02-25 | Gerhard Prante | Director | Sell | −1,150 | −$2.38K |
| 2025-02-24 | Gerhard Prante | Director | Sell | −1,150 | −$2.53K |
| 2025-02-21 | Gerhard Prante | Director | Sell | −1,150 | −$2.70K |
| 2025-02-20 | Gerhard Prante | Director | Sell | −1,150 | −$2.97K |
| 2025-02-19 | Gerhard Prante | Director | Sell | −2,300 | −$5.80K |
| 2025-02-18 | Gerhard Prante | Director | Sell | −1,150 | −$2.99K |
| 2025-02-14 | Gerhard Prante | Director | Sell | −1,150 | −$2.91K |
| 2025-02-13 | Gerhard Prante | Director | Sell | −1,150 | −$2.82K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Rory B Riggs | Director | 14,940,447 | $21.07M |
| Jean-Pierre Jules Lehmann | Director | 2,450,975 | $3.46M |
| Mark Terrence Finn | Director | 1,222,566 | $1.72M |
| Craig Wichner | CEO | 894,309 | $1.26M |
| Peter Beetham | Interim CEO, Pres & COO | 686,825 | $968.42K |
| Gregory Francis William Gocal | Chief Scientific Officer & EVP | 422,890 | $596.27K |
| Jason Stokes | CAO, Gen Csl & Corp Secy | 167,865 | $236.69K |
| Carlo Broos | CFO | 154,275 | $217.53K |
| Noel Sauer | Sr VP, Research | 139,879 | $197.23K |
| Gerhard Prante | Director | 104,945 | $147.97K |
| Thomas Urban | Director | 64,748 | $91.29K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CBUS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.